TD Cowen Initiates Coverage on vTv Therapeutics (NASDAQ:VTVT)

TD Cowen initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $67.00 price target on the biotechnology company’s stock. TD Cowen’s target price points to a potential upside of 56.84% from the company’s current price.

Several other analysts have also recently commented on the company. Cowen began coverage on vTv Therapeutics in a report on Monday. They issued a “buy” rating for the company. Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a research report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $47.00 price target (up previously from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Finally, BTIG Research began coverage on vTv Therapeutics in a report on Wednesday, November 19th. They set a “buy” rating and a $40.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, vTv Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $51.33.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $42.72 on Monday. vTv Therapeutics has a 1 year low of $13.20 and a 1 year high of $44.00. The company’s 50 day simple moving average is $31.37 and its 200 day simple moving average is $22.77. The company has a market capitalization of $168.32 million, a price-to-earnings ratio of -12.87 and a beta of 0.48.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Hedge Funds Weigh In On vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. Baker BROS. Advisors LP increased its position in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 148,314 shares of the biotechnology company’s stock after acquiring an additional 51,000 shares during the period. Baker BROS. Advisors LP owned about 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.